KBC Group NV Sells 13,472 Shares of Illumina, Inc. $ILMN

KBC Group NV lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 31.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 29,378 shares of the life sciences company’s stock after selling 13,472 shares during the period. KBC Group NV’s holdings in Illumina were worth $2,803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cerity Partners LLC increased its stake in Illumina by 2.6% in the first quarter. Cerity Partners LLC now owns 25,951 shares of the life sciences company’s stock valued at $2,059,000 after acquiring an additional 661 shares during the period. New York State Common Retirement Fund boosted its holdings in Illumina by 36.8% during the first quarter. New York State Common Retirement Fund now owns 138,993 shares of the life sciences company’s stock valued at $11,028,000 after purchasing an additional 37,388 shares in the last quarter. Stephens Inc. AR boosted its holdings in Illumina by 12.4% during the first quarter. Stephens Inc. AR now owns 7,447 shares of the life sciences company’s stock valued at $591,000 after purchasing an additional 824 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Illumina by 1,771.4% in the 1st quarter. Larson Financial Group LLC now owns 1,310 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,240 shares during the period. Finally, Archer Investment Corp acquired a new position in shares of Illumina in the 1st quarter worth approximately $67,000. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ILMN. UBS Group boosted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Evercore ISI upped their target price on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research report on Tuesday, August 12th. TD Cowen lifted their price target on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. Finally, Daiwa America cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $115.00.

Illumina Stock Performance

Illumina stock opened at $120.67 on Friday. The stock has a 50-day simple moving average of $102.84 and a 200 day simple moving average of $95.99. The stock has a market capitalization of $18.44 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 2.34 and a beta of 1.42. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company posted $1.14 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb acquired 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.